Daratumumab for autoimmune diseases: a systematic review
Authors' conclusion
Targeting CD38 via daratumumab is a new promising therapeutic option in therapy refractory autoimmune diseases.
Study context
- Population
- Patients with therapy-refractory autoantibody-mediated autoimmune diseases (24 different diseases; median of 5 previous therapies)38 publications
- Participants
- 83 patients
- Outcome
- Remission or improvement of disease
Methodological detailsprotocolised, PRISMA guidelines, Medline and Embase, Median number of daratumumab applications 4, mainly IV (87%), Concomitant GC in 64%, IV immunoglobulins (33%) and RTX (17%)
- Protocolised
- PRISMA guidelines
- Medline and Embase
- Median number of daratumumab applications 4, mainly IV (87%)
- Concomitant GC in 64%, IV immunoglobulins (33%) and RTX (17%)
Pooled result
As reported in the abstract
Remission or improvement of disease reported
81%
Further pooled results
Autoantibody depletion or reduction
- Autoantibody depletion or reduction stated
- 52%
Death
- Death (patients)
- 3
- Death (proportion)
- 3%
Safety
- Any adverse event
- 45%
- Application-associated reaction
- 20%
- Infection
- 19%
- Hypogammaglobulinaemia
- 33%
Original publication
Daratumumab for autoimmune diseases: a systematic review. RMD Open. Published 14 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →